Key Publications

  • Da Silva CG, Rueda F, Löwik CW, Ossendorp F, Cruz LJ.Combinatorial prospects of nano-targeted chemoimmunotherapy.Biomaterials. 2016 Jan 9;83:308-320.
  • Luis J. Cruz, Marieke  A. Stammes, Ivo Que, Ermond R. van Beek, Vicky T. Knol-Blankevoort, Thomas J. A. Snoeks, Alan Chan, Eric L. Kaijzel, Clemens W. G. M. Löwik. Effect of PLGA NP Size on Efficiency to Target Traumatic Brain Injury. J Control Release. 2016 Feb 10;223:31-41.
  • Kleinovink JW, van Driel PB, Snoeks TJ, Prokopi N, Fransen MF, Cruz LJ, Mezzanotte L, Chan A4, Löwik CW3, Ossendorp F. Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors. Clin Cancer Res. 2015 Nov 6.
  • Xie B, Stammes MA, van Driel PB, Cruz LJ, Knol-Blankevoort VT, Löwik MA, Mezzanotte L, Que I, Chan A, van den Wijngaard JP, Siebes M, Gottschalk S, Razansky D, Ntziachristos V, Keereweer S, Horobin RW, Hoehn M, Kaijzel EL, van Beek ER, Snoeks TJ, Löwik CW. Necrosis avid near infrared fluorescent cyanines for imaging cell death and their use to monitor therapeutic efficacy in mouse tumor models.Oncotarget. 2015 Nov 17;6(36):39036-49.
  • Srinivas M, Tel J, Schreibelt G, Bonetto F, Cruz LJ, Amiri H, Heerschap A, Figdor CG, de Vries IJ. PLGA-encapsulated perfluorocarbon nanoparticles for simultaneous visualization of distinct cell populations by 19F MRI. Nanomedicine (Lond). 2015 Aug;10(15):2339-48.
  • M. Srinivas, G. Lajoinie, Luis J. Cruz, Eric A.W van Dinther, Yusuf Dolen, Arend Heerschap, M. Versluis, C.L. de Korte,  C. G. Figdor, I.J.M. de Vries. Non-gaseous perfluorocarbon nanoparticles for ultrasound, 19F MRI and fluorescence imaging of migratory cells in vivo. Nature Nanotechnology,(in revision).
  • Bob C Hamans, Dennis CJ Waalboer, Marloes Wennemers, Luis J Cruz, William Leenders, Houshang Amiri, Paul N Span, Floris PJT Rutjes, Arend Heerschap. Trifluoro-pimonidazole: a tissue hypoxia marker suitable for both in vivo 19F MR imaging and ex vivo immunohistochemistry. PLoS ONE, (in revision).
  • Rosalia RA, Cruz LJ, van Duikeren S, Tromp AT, Silva AL, Jiskoot W, de Gruijl T, Löwik C, Oostendorp J, van der Burg SH, Ossendorp F. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials. 2015 Feb;40:88-97.
  • Cruz LJ, Tacken PJ, Zeelenberg IS, Srinivas M, Bonetto F, Weigelin B, Eich C, de Vries IJ, Figdor CG. Tracking targeted bimodal nanovaccines: immune responses and routing in cells, tissue, and whole organism. Mol Pharm. 2014 Dec 1;11(12):4299-313.
  • Cruz LJ, Rosalia RA, Kleinovink JW, Rueda F, Löwik CW, Ossendorp F. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: A comparative study. J Control Release.2014 Jul 25;192C:209-218.
  • Aarntzen EH, Srinivas M, Bonetto F, Cruz LJ, Verdijk P, Schreibelt G, van de Rakt M, Lesterhuis WJ, van Riel M, Punt CJ, Adema GJ, Heerschap A, Figdor CG, Oyen WJ, de Vries IJ. Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clin Cancer Res. 2013, 15;19(6):1525-33 .
  • Tel J, Schreibelt G, Sittig SP, Mathan TS, Buschow SI, Cruz LJ, Lambeck AJ, Figdor CG, de Vries IJ. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood.2013, 17;121(3):459-67
  • Cruz LJ, Tacken PJ, Pots JM, Torensma R, Buschow SI, Figdor CG. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN. Biomaterials.2012 Jun;33(16):4229-39.
  • Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, Adema GJ, Brown GD, Figdor CG, de Vries IJ. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-) presentation by human blood BDCA3+ myeloid dendritic cells. Blood. 2012 Mar 8;119(10):2284-92.
  • Snoeks TJ1, van Beek E, Que I, Kaijzel EL, Löwik CW. Bioluminescence imaging of bone metastasis in rodents. Methods Mol Biol. 2012;816:507-15
  • Cruz LJ*, Tacken PJ*, Zeelenberg IS*, et al.Figdor CG. Targeted delivery of Toll-like receptor ligands to human and mouse dendritic cells strongly enhances adjuvanticity.Blood. 2011 Dec 22;118(26):6836-44. (*equally contributing authors).
  • Tacken PJ, Ginter W, Berod L, Cruz LJ, Joosten B, Sparwasser T, Figdor CG, Cambi A. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation and cross-presentation. Blood 2011 ;118(15):4111-9.
  • Cruz LJ, Tacken PJ, Fokkink R, Figdor CG.The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials2011, 32(28):6791-803.
  • Srinivas M, Cruz LJ, Bonetto F, Heerschap A, Figdor CG, de Vries IJ. Customizable, multi-functional fluorocarbon nanoparticles for quantitative in vivo imaging using 19F MRI and optical imaging.Biomaterials 2010, 31(27):7070-7.
  • Cruz LJ, Cruz LJ, Tacken PJ, Fokkink R, Joosten B, Stuart MC, Albericio F, Torensma R, Figdor CG. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro.J Control Release2010, 144(2):118-26. (cover feature).